Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 5, 2011 - Issue 2
Submit an article Journal homepage
172
Views
17
CrossRef citations to date
0
Altmetric
Perspective

Pulmonary hypertension secondary to interstitial lung disease

Oksana A Shlobin Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Falls Church, VA 22042, USA; Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Falls Church, VA 22042, USA
&
Steven D Nathan Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Falls Church, VA 22042, USA;[email protected]
Pages 179-189 | Published online: 09 Jan 2014

References

  • American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. General principles and recommendations. Am. J. Respir. Crit. Care Med.165, 277–304 (2002).
  • Thannickal VJ, Toews GB, White ES et al. Mechanisms of pulmonary fibrosis. Annu. Rev. Med.55, 395–417 (2004).
  • Strange C, Highland K. Pulmonary hypertension in ILD. Curr. Opin. Pulm. Med.11, 452–455 (2005).
  • Simmoneau G, Robins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Card.54(1), S43–S54 (2009).
  • Shapiro S. Management of pulmonary hypertension resulting from interstital lung disease. Curr. Opin. Pulm. Med.9, 426–430 (2003).
  • McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol.53(17), 1573–1619 (2009).
  • Chronic cor pulmonale: report of an expert committee. Circulation27(4), 594–615 (1963).
  • Fartoukh M, Humbert M, Capron F et al. Severe pulmonary hypertension in histiocytosis X. Am. J. Respir. Crit. Care Med.161, 216–223 (2000).
  • Dauriat G. Lung transplantation for pulmonary Langerhans cell histiocytosis: a multicenter analysis. Transplantation81(5), 746–750 (2006).
  • Chaowalit N, Pellikka PA, Decker PA et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo. Clin. Proc.79(10), 1269–1275 (2004).
  • Harari S, Brenot F, Barberis M et al. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest111(4), 1142–1144 (1997).
  • Nadrous HF, Pellikka PA, Krowka MJ et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest128, 2393–2399 (2005).
  • Lettieri C, Nathan SD, Barnett S et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest129, 746–752 (2006).
  • Shorr AF, Wainright JL, Cors CS et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur. Respir. J.30(4), 715–721 (2007).
  • Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett S. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest131(3), 657–663 (2007).
  • Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis.62, 1088–1093 (2003).
  • Chang B, Wigley FM, White B et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J. Rheumatol.30, 2398–2405 (2003).
  • Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am. J. Respir. Crit. Care Med.179, 151–157 (2009).
  • Trad S, Amoura Z, Beigelman C et al. PAH is a major mortality factor in diffuse systemic sclerosis, independent of intersitial lung disease. Arthritis Rheum.54, 184–191 (2006).
  • Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum.48(2), 516–522 (2003).
  • Handa T, Nagai S, Miki S et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest129, 1246–1252 (2006).
  • Shorr AF, Helman DL, Davies DB et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur. Respir. J.25, 783–788 (2005).
  • Shorr AF, Davies DB, Nathan SD. Predicting mortailty in patients with sarcoidosis awaiting lung transplantation. Chest124, 922–928 (2003).
  • Sulica R, Teirstein AS, Kakarla S et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest128, 1483–1489 (2005).
  • Taveira-DaSilva AM, Hathaway OM, Sachdev V et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest132(5), 1573–1578 (2007).
  • Portier F, Lerebours-Pigeonniere G, Thiberville L et al. Sarcoidosis simulating pulmonary veno-occlusive disease. Rev. Mal. Respir.8(1), 101–102 (1991).
  • Morgan JM, Griffiths M, du Bois RM et al. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest99, 551–556 (1991).
  • Nunes H, Humbert M, Capron F et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax61, 68–74 (2006).
  • Colombat M, Mal H, Groussard O et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum. Path.38(1), 60–65 (2007).
  • Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarc. Vasc. Diff. Lung Dis.26, 7–19 (2009).
  • Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest113, 237–240 (1998).
  • Farber HW, Graven KK, Kokolski G, Korn JH. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J. Rheumatol.26, 1195–1196 (1999).
  • Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog. Cardiovasc. Dis.45, 225–234 (2002).
  • Mahapatra S, Nishimura RA, Sorajja P et al. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J. Am. Coll. Cardiol.47(4), 799–803 (2006).
  • Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc. Am. Thorac. Soc.3, 364–372 (2006).
  • Farkas L, Gauldie J, Voelkel NF et al. Pulmonary hypertension and idiopathic pulmonary fibrosis – a tale of angiogenesis, apoptosis and growth factors. Am. J. Respir. Cell Mol. Biol. DOI:10.1165/rcmb.2010-0365TR (2010) (Epub ahead of print).
  • Yamakami T, Taguchi O, Gabazza EC et al. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease: relation with pulmonary HTN during exercise. Eur. Respir. J.10, 2055–2060 (1997).
  • MacLean MR. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? J. Lab. Clin. Med.134, 105–114 (1999).
  • Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med.175, 875–880 (2007).
  • Nathan SD, Shlobin OA, Ahmad S et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest131, 657–663 (2007).
  • Galie N, Manes A, Farahani KV et al. PAH associated with CTDs. Lupus14, 713–717 (2005).
  • Fahy GJ, Marwick T, McCreery CJ et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest109, 62–66 (1996).
  • Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in ling fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med.170(4), 360–365 (2004).
  • Magro CM, Allen J, Pope-Harman A et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am. J. Clin. Pathol.119, 556–567 (2003).
  • Panos R. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med.88(4), 396–404 (1990).
  • Nathan SD, Barnett SD, Urban BA, Nowalk C, Moran BR, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest123, 1758–1763 (2003).
  • Mejía M, Carrillo G, Rojas-Serrano J et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest136(1), 10–15 (2009).
  • Perez-Padilla R, West P, Lertzman M et al. Breathing during sleep in patients with interstitial lung disease. Am. Rev. Respir. Dis.132, 224–229 (1985).
  • Minai OA, Santucruz JF, Thuita L et al. Severe pulmonary hypertension in IPF: characteristics and implications. Presented at: ISHLT 29th Annual Meeting and Scientific Sessions. Paris, France, 22–25 April 2009.
  • Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension. Chest138, 1078–1085 (2010).
  • Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Resp. Med.103, 180–186 (2009).
  • Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann. Rheum. Dis.62, 97–99 (2003).
  • Zisman DA, Karlamangla AS, Ross DJ et al. High resolution CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest132, 773–779 (2007).
  • Yock P. Noninvasive estimation of the right ventriculat systolic pressure by doppler ultrasound in patients with tricuspid regurgitation. Circulation70(4), 657–662 (1984).
  • Fisher MR, Forfia PR, Chamera E et al. Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am. J. Respir. Crit. Care Med.179(7), 615–621 (2009).
  • Arcasoy S, Chrstie J, Ferrari V et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med.167, 735–740 (2003).
  • Corte TJ, Wort SJ, Gatzoulis MA et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax64(10), 883–888 (2009).
  • Devaraj A, Wells AU, Meister MG et al. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. Radiology254(2), 609–616 (2010).
  • Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.43, 40S–47S (2004).
  • Badesch DB, Abman SH, Simonneau G et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest131, 1917–1928 (2007).
  • Hamada K, Nagai S, Tanaka S et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest131, 650–656 (2007).
  • Bye PT, Issa F, Berthon-Jones M et al. Studies of oxygenation during sleep in patients with interstitial lung disease. Am. Rev. Respir. Dis.129, 27–32 (1984).
  • Papadopoulis CE, Pitsiou G, Karamitsos TD et al. Left ventricular diastolic dysfunction in IPF: a tissue doppler ECG study. Eur. Respir. J.31, 701–706 (2008).
  • Corte TJ, Talbot S, Wort SJ et al. Nocturnal desaturation is associated with pulmonary hypertension in patients with mild to moderate interstitial lung disease. Am. J. Respir. Crit. Care Med.179, A4057 (2009).
  • Shitrit D, Rusanov V, Peled N et al. The 15-step oximetry test: a reliable tool to identify candidates for lung transplantation among patients with idiopathic pulmonary fibrosis. J. Heart Lung Transplant.28, 328–333 (2009).
  • Kliment CR, Oury TD. Oxidative stress, extracellualr matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med.49(5), 707–717 (2010).
  • Benyuones B, Crestani B, Couvelard A, et al. Steroid-responsive pulmonary hypertension in a patient with Langerhans cell granulomatosis (histiocytosis X). Chest110, 284–286 (1996).
  • Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest97, 500–502 (1990).
  • Gluskowski J, Hawrylkiewicz I, Zych D, Zielinski J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur. Respir.3, 403–407 (1990).
  • Kubo H, Nakayama K, Yanai M et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest128, 1475–1482 (2005).
  • Barst RJ, Gibbs JS, Ghofrani HA et al. Updated evidence-based tratment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol.54(Suppl. 1), S78–S84 (2009).
  • Hoeper MM, Barbera JA, Channick RN et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J. Am. Coll. Cardiol.54, S85–9S6 (2009).
  • Jackson RM, Glassberg MK, Ramos CF et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung188(2), 115–123 (2010).
  • Collard HR, Anstrom KJ, Schwarz MI et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest131, 897–899 (2007).
  • Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet360(9337), 895–900 (2002).
  • Idiopathic Pulmonary Fibrosis Clinical Research Network; Zisman DA, Schwarz M, Anstrom KJ et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med.363(7), 620–628 (2010).
  • Krowka MJ, Ahmad S, Andrade JA et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis. Presented at: 36th ACCP Annual Meeting. San Francisco, CA, USA, 9–11 September 2007.
  • Olschewski H, Ghofrani HA, Walmrath D et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med.160, 600–607 (1999).
  • King TE Jr, Behr J, Brown KK et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.177, 75–81 (2008).
  • King TE. The BUILD-3 trial: prospective, randomized, double-blind, placebo-controlled study of bosentan in IPF. Presented at: American Thoracic Symposium. New Orleans, LA, USA, 14–19 May 2010.
  • Badesch DB, Feldman J, Keogh A et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med.179, A3357 (2009).
  • Preston IR, Klinger JR, Landzberg MJ et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest120, 866–872 (2001).
  • Fisher KA, Serlin DM, Wilson KC et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest130(5), 1481–1488 (2006).
  • Minai O, Sahoo D, Chapman J et al. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir. Med.102(7), 1015–1020 (2008).
  • Barnett CF, Bonura EJ, Nathan SD et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest135(6), 1455–1461 (2009).
  • Milman, N, Burton CM, Iversen M et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J. Heart Lung Transplant.27(3), 329–334 (2008).
  • Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex. Heart Inst. J.32(3), 405–410 (2005).
  • Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarc. Vasc. Diff. Lung Dis.23, 108–116 (2006).
  • Judson MA, Ford H, Donohue JM et al. Ambrisentan for sarcoidosis associated pulmonary hypertension (SAPH). Presented at: American Thoracic Symposium. New Orleans, LA, USA, 14–19 May 2010.
  • Saggar R, Belperio JA, Shapiro SS et al. A single center, prospective, open label, pilot study evaluating the safety and efficacy of IV/SQ treprostinil in the treatment of pulmonary arterial hypertension associated with advanced interstitial lung disease. Presented at: American Thoracic Symposium. New Orleans, LA, USA, 14–19 May 2010.
  • Hoeper MM, Halank M, Wilkens H et al. Riociguat for patients with pulmonary hypertension associated with interstitial lung disease. Presented at: American Thoracic Symposium. New Orleans, LA, USA, 14–19 May 2010.
  • Nathan SD, Barnett SD, Saggar R et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respir. Med.102, 1305–1310 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.